← Home
The reasons are not apparent
+8.23% closed: 2024-10-30
Chugai Earnings: Full-Year Guidance Revised Upward; Fair Value Raised 13% to JPY 5,900. Narrow-moat Chugai’s third-quarter earnings exceeded our expectations due to strong overseas sales of immunology drug Actemra and income from disposal of product rights.
+7.11% closed: 2025-02-15
Reasons are not apparent
+6.52% closed: 2025-02-24
Reasons are not apparent
+5.32% closed: 2024-11-08
Reasons are not apparent
Stock Swings
Price Drops
No drop incidentsPrice Hikes
+22.25% 2025-04-18+8.23% closed: 2024-10-30
Chugai Earnings: Full-Year Guidance Revised Upward; Fair Value Raised 13% to JPY 5,900. Narrow-moat Chugai’s third-quarter earnings exceeded our expectations due to strong overseas sales of immunology drug Actemra and income from disposal of product rights.
+7.11% closed: 2025-02-15
Reasons are not apparent
+6.52% closed: 2025-02-24
Reasons are not apparent
+5.32% closed: 2024-11-08
Reasons are not apparent
Wait! There's more — sign up for free or log in